U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07371403) titled 'MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia' on Jan. 11.
Brief Summary: Single-arm, prospective, open-label feasibility study evaluating the technical and operational feasibility of manufacturing autologous CD19-directed CAR-T cells (MB-CART19.1) at the point of care for the treatment of relapsed or refractory B-ALL in pediatric and adult patients.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia Recurrent
Acute Lymphoblastic Leukemia Refractory
Acute Lymphoblastic Leukemia Not Having Achieved Remission
Acute Lymphoblastic Leukemia Wi...